Cingulate Inc. (CING) shares are experiencing a significant rise on Friday, fueled by the company’s unveiling of a groundbreaking Precision Timed Release (PTR) technology designed to revolutionize ADHD drug delivery. This innovative technology aims to enhance the onset and effectiveness of existing ADHD treatments, attracting the attention of investors who see potential in CING’s advancements.
The company’s stock has been on an upward trajectory, with Zacks Small-Cap Research issuing a note earlier this week, valuing CING at a substantial $70. This positive sentiment from a reputable research firm adds further weight to the stock’s momentum.
Trading Volume:
CING opened at $6.63 and has traded within a day range of $6.01 to $9.69. The 50-day moving average sits at $5.81. The company’s short interest has seen a notable decrease of 75.73% since its last report, now standing at 51,000 shares, representing 3.18% of its float.Key Metrics Recap:
*
Market Cap (Previous Close):
$11.12 million*
52-Week Range:
$1.80 – $187.2*
Float:
1.622 million shares*
Institutional Ownership:
1.13%*
Insider Ownership:
14.27%How to Buy CING Stock:
Acquiring shares of CING is typically done through a brokerage account. Numerous trading platforms are available, and many offer the ability to buy ‘fractional shares,’ allowing you to own portions of a stock without purchasing an entire share. This is especially beneficial for stocks with high share prices, such as Berkshire Hathaway or Amazon.com, where a single share can cost thousands of dollars. Brokerages enable you to invest smaller amounts in these stocks.
In the case of CING, currently trading at $8.2, a $100 investment would grant you approximately 12.2 shares.
